Second Genome: Joseph Dal Porto

Joseph Dal Porto has been appointed as CSO of Second Genome. Previously, he was VP at Pfizer's emerging science & innovation division and site head of Pfizer's Centers for Therapeutic Innovation. Prior to that, he was a cofounder and director of preclinical research and development at Modus BioMedicine, a spinout from Roche. Dal Porto holds a PhD in microbiology and immunology from the University of Maryland School of Medicine and a BS in biochemistry from Johns Hopkins University.